Clomiphene (Clomid) vs Enclomiphene

Mechanism

Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.

Standard Dosing

Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.

Timing

Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.

Cycle Duration

PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.

Side Effects

• Visual disturbances (blurred vision, floaters, light sensitivity — due to zuclomiphene accumulation)
• Mood swings and emotional lability
• Headache
• Nausea
• Hot flashes
• Gynecomastia (paradoxical, from zuclomiphene's estrogenic activity)
• Elevated estradiol (zuclomiphene accumulation)

Contraindications

• Active liver disease or hepatic dysfunction
• Undiagnosed abnormal uterine bleeding (if prescribed to females)
• Ovarian cysts (females)
• Known hypersensitivity to clomiphene
• Pituitary tumor
• Primary hypogonadism (testicular failure — clomiphene only works in secondary hypogonadism)

Best Stacking Partners

Mechanism

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Standard Dosing

Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Timing

Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Cycle Duration

Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Side Effects

• Headache
• Hot flashes
• Nausea (less common than racemic clomiphene)
• Elevated estradiol (from increased testosterone substrate for aromatase)
• Rare visual disturbances (significantly less than racemic clomiphene)

Contraindications

• Primary hypogonadism (elevated gonadotropins, testicular failure)
• Severe hepatic impairment
• Known hypersensitivity to clomiphene isomers
• Pituitary tumors
• Vision changes or thrombotic history warrant caution

Best Stacking Partners